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by Manfred Metzler,*t Gunter Blaich,* and Angelika M.
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MaleSyriangolden hamsterschronically exposedtocertainsynthetic estrogens suchasdiethylstilbestrol
(DES) or 17a-ethinylestradiol (EE2) and fed a diet containing 7,8-benzoflavone (BF) develop a high in-
cidence oflivertumors. No suchtumors arefound in animalstreated with estrogen orBF alone. To clarify
the role ofmetabolic activation ofthe estrogen and BF in the mechanism ofhepatocarcinogenesis in this
animal model, the effects of pretreatment with DES and EE2 alone and in combination with BF on the
metabolism of DES, EE2, and BF in hepatic microsomes, isolated hepatocytes, and hamster bile were
studied. Hamsters were pretreated for up to 32 weeks. The results clearly show that DES metabolism was
not significantly modified under any pretreatment regimen. EE2 metabolism exhibited a slight increase
in 2-hydroxylation after pretreatment with BF and with BF plus EE2. The most pronounced effect was
observed in BF metabolism after pretreatment with BF, with BF plus DES, and with BF plus EE2: the
metabolic rate was increased and several new metabolites that were not found in untreated or estrogen-
pretreated animals were formed. These metabolites were tentatively identified as BF-dihydrodiol and
dihydroxy-BFs. The formation ofthese new BF metabolites was accompanied by achange in the activities
ofcertain cytochrome P450 isoenzymes in hamster liver microsomes. The results ofthis study imply that
metabolic activation of BF rather than of the estrogens plays an important role in the mechanism of
carcinogenesis in this animal liver tumor model.
Introduction
Several observations suggest that the formation of
reactive metabolites is important in the mechanism of
estrogen carcinogenesis (1-3). However, unequivocal
evidence is still lacking. A rather convincing argument
would be that modulations in the metabolic activation
of estrogens were correlated with the ability to induce
tumors. A recently described animal tumor model ap-
pears to be of particular interest in this context: male
Syrian golden hamsters chronically exposed to certain
synthetic estrogens such as diethylstilbestrol (DES) or
17a-ethinylestradiol (EE2) andfed adietcontaining7,8-
benzoflavone (BF) develop a high incidence (80-100%)
of hepatic tumors after 6 to 8 months (4). Virtually no
liver tumors were observed in animals treated with es-
trogen or BF alone.
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To clarify whether the metabolism of the estrogen
and BF is modulated under conditions oftumor induc-
tion, we have studied the effects of pretreatment with
BF, DES, EE2, BF plus DES, and BF plus EE2 on the
metabolic pattern of radioactively labeled DES, EE2,
and BF in hamster hepatic microsomal preparations,
isolated hepatocytes, and hamsterbileinvivo. The dos-
ing regimen of pretreatment was the same as used in
the carcinogenicity study (4), i.e., DES and EE2 were
implanted SC every 3 months as 20-mg pellets and 30-
mg pellets, respectively, and BF was administered in
the diet at 0.4%. The effects of the various pretreat-
ments were also measured on the activity of several
cytochrome P-450 isoenzymes in hepatic microsomes.
The results ofthese studies, which have been reported
in part elsewhere (5-10), are briefly reviewed in this
paper.
Results
DES Metabolism
Previous studies in the Syrian hamster in vivo (11)
and with hepatic and renal hamster microsomes (12)
have shown that DES is metabolized to a variety of
oxidative products [e.g., 1-hydroxy-DES, 3'-hydroxy-METZLER, BLAICH, AND TRITSCHER
DES, Z,Z-dienestrol (Z,Z =DIES), and 1-hydroxy-Z,Z-
DIES]. These metabolites can be readily separated and
quantified by HPLC (12). When the metabolism of 14C-
DES was studied in male hamsters pretreated with
DES alone, BF alone, and DES plus BF for 8, 20, and
32 weeks, neither hepatic microsomes (7) nor hepato-
cytes (9) elicited any alteration in the pattern of DES
metabolites as compared to untreated controls. Nonex-
tractable binding to microsomal protein was not in-
creased under any of these conditions. This suggests
that the pretreatment regimen leading to tumor for-
mation in the hamster liver is not accompanied by an
increased metabolic activation of DES. In vivo studies
with pretreated hamsters using biliary DES metabo-
lites as probes for hepatic biotransformation support
this notion (6).
EE2 Metabolism
EE2 can be metabolically activated at the aromatic
ring through the formation ofthe catechol estrogens 2-
hydroxy-EE2 and 4-hydroxy-EE2 and their further ox-
idation totherespective semiquinones and quinones (1).
In addition, oxidation of the ethinyl group may yield
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reactive metabolites. A recent study (13) demonstrated
thatpretreatment ofmale Syrian hamsters with BF for
4 months led to a shift in the pattern ofmicrosomal 14C-
EE2 metabolites. A 1.5-fold increase in the formation
of2-hydroxy-EE2 and a slight increase in the extent of
irreversible binding ofradioactivity to microsomal pro-
tein suggested enhanced metabolic activation of EE2
after pretreatment with BF. An approximately 2-fold
increase intheformationof2-hydroxy-EE2inmaleham-
ster liver microsomes was observed in another study afterpretreatment for3 months with EE2 alone orwith
EE2plus BF (10). However, inthe latterstudy, binding
to microsomal protein was found to be decreased about
2-foldinmicrosomes from allpretreated animals as com-
pared to controls.
BF Metabolism
Hepatic microsomes from untreated male hamsters
metabolize 14C-BF to at least five products, as shown
by HPLC (Fig. 1). The radioactive peaks were collected
and subjected to GC/MS after trimethylsilylation. 6-
Hydroxy-BF and 7-hydroxy-BF were unambiguously
identified through their mass spectra and co-chroma-
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FIGURE 1. Radio-HPLC profiles of BF metabolites generated by hamster liver microsomes after various pretreatments. Left panel: exper-
iments with DES. Right panel: experiments with EE2. The small differences in retention times between identical samples are due to slight differences in the HPLC conditions. For further details see Blaich et al. (14).
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FIGURE 2. Oxidative pathways in BF metabolism possibly leading to reactive intermediates.
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FIGURE 3. Effect of pretreatment (20 weeks) on the levels and ac-
tivities ofvarious enzymes in hamster liver microsomes (mean ±
SD of five animals). ECOD, 7-ethoxycoumarin-O-deethylase;
AHH, aromatic hydrocarbon hydroxylase; EROD, 7-ethoxyreso-
rufin-O-deethylase; PROD, 7-pentoxyresorufin-O-dealkylase.
tography with authentic reference compounds in HPLC
and GC. Metabolites II, V, and VI (Fig. 1) were ten-
tatively identified as BF-7,8-dihydrodiol, a dihydroxy-
BF, and4'-hydroxy-BF, respectively. The massspectra
and other evidence for the proposed structures ofthese
products are reported in detail elsewhere (14).
Pretreatment of hamsters with DES or EE2 did not
affect the hepatic microsomal metabolism of BF (Fig.
1). In contrast, pretreatment with BF led to a marked
quantitative and qualitative alteration ofthe metabolic
pattern: formation of7-hydroxy-BF was enhanced, and
at least three new metabolites (I, III, and IV, Fig. 1)
were observed. Preliminaryidentification suggests that
metabolite I is BF-5,6-dihydrodiol, and metabolites III
and IV are dihydroxy-BFs ofunknown structure (14).
A tentative metabolic scheme of the oxidative metab-
olism of BF is depicted in Figure 2.
Most interestingly, the pattern of oxidative BF me-
tabolites observed after pretreatment with BF alone
was also found in microsomes ofhamsters treated with
BF plus DES and BF plus EE2, suggesting that the
new metabolites are indeed formed under conditions of
liver tumor induction (Fig. 1). Moreover, the effect of
pretreatment with BF plus estrogen on BF metabolism
was the same in hepatic microsomes and in freshly iso-
lated hepatocytes (9).
Enzyme Activities
The levels of cytochromes P-450 and b5 and the en-
zyme activities of 7-ethoxycoumarin-O-deethylase
(ECOD), aromatic hydrocarbon hydroxylase (AHH), 7-
ethoxyresorufin-O-deethylase (EROD), and 7-pentoxy-
resorufin-O-dealkylase (PROD) were measured in mi-
crosomes from male hamsters after pretreatment with
BF alone, DES alone, and BF plus DES for 8 and 20
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weeks. The effects were about the same after both pe-
riods ofpretreatment. As shown in Figure 3, treatment
with BF alone increased both cytochrome P-450 and b5
levels, whereas pretreatment with DES did not affect
cytochrome b5, but decreased P-450. Combined pre-
treatment led to an intermediate effect.
After pretreatment with BF, the microsomal activi-
ties ofEROD and PROD, but not ofECOD and AHH,
were significantly induced (Fig. 3). Microsomes from
DES-primed animals showed a significant decrease in
ECOD, EROD, andPRODactivities; AHHactivitywas
not affected. Thecombined pretreatment with DES and
BF had different effects ontheactivities ofthe different
enzymes. ECOD and AHH showed no significant alter-
ation; EROD and PROD were clearlyinduced, although
to a lesser extent than in animals pretreated with BF
alone.
Discussion
Theinduction ofhepatocellularcarcinomasinthemale
Syrian golden hamsterby simultaneous treatment with
estrogen and BF has been proposed as an animal model
for liver tumors in women taking oral contraceptives
(4). The mechanism of tumor formation in this animal
model is as yet unclear.
Ourdataindicate that pretreatment ofhamsters with
BF results in a marked increase in the level of total
cytochrome P-450 and in the activities ofvarious P-450
isoenzymes inthe liver. AlthoughBF actsasaninducer,
themetabolismofDESremainsunaffected. Thisimplies
that the P-450 isoenzymes inducible by BF are not pri-
marily involved in DES metabolism.
A somewhat different situation appears to exist for
EE2, because BF induction leads to an increase in 2-
hydroxylation, a pathway possibly involved in the met-
abolic activation of steroidal estrogens. However, it is
unlikely that the observed change in EE2 metabolism
isthe solereasonforthehighincidenceofhepatocellular
carcinomas observed after combined treatment with
EE2 and BF because the same pathway is stimulated
after pretreatment with EE2 alone, which gives rise to
only a very low incidence of liver tumors (4). Thus, it
must be concluded that other factors are involved in
hepatocarcinogenesis in this animal model.
The striking alteration of BF metabolism observed
underthe conditions ofhepatictumorformation suggest
that reactive metabolites of BF may play an important
role. According to the preliminary identification, the
altered metabolism yields dihydrodiols and dihydroxy-
lated BFs that may give rise to reactive electrophiles
such as dihydrodiol epoxides and semiquinones/qui-
nones.
It is interesting in this context that rat liver micro-
somes induced by 2,3,7,8-tetrachlorodibenzodioxin
(TCDD) yield similar BF metabolites, which have been
demonstrated to be clastogenic and to produce DNA
adducts in Chinese hamster ovary celis (15,16). As no
hepatic tumors were obtained with BF alone (4), it is
likely that BF acts as a pure initiator in the hamster
liver, and the promoting activity ofDES is required for
tumormanifestation. Asimilarsituation appearstopre-
vail for the treatment with EE2 and BF, with the ex-
ception that EE2 may be a weak initiator in its own
right, as discussed above, in addition to acting as a
promotor. In accordance with this hypothesis is the ob-
servation that treatment with EE2 plus BF leads to a
higher tumor incidence and a shorter latency period
than treatment with DES plus BF (4).
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